These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33513349)

  • 1. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
    Sanclemente M; Nieto P; Garcia-Alonso S; Fernández-García F; Esteban-Burgos L; Guerra C; Drosten M; Caleiras E; Martinez-Torrecuadrada J; Santamaría D; Musteanu M; Barbacid M
    Cancer Cell; 2021 Mar; 39(3):294-296. PubMed ID: 33513349
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
    Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
    J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    Orue A; Chavez V; Strasberg-Rieber M; Rieber M
    BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.
    Kasiappan R; Shih HJ; Chu KL; Chen WT; Liu HP; Huang SF; Choy CO; Shu CL; Din R; Chu JS; Hsu HL
    Mol Cancer Res; 2009 Apr; 7(4):536-48. PubMed ID: 19372582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
    Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
    Meinhardt AL; Munkhbaatar E; Höckendorf U; Dietzen M; Dechant M; Anton M; Jacob A; Steiger K; Weichert W; Brcic L; McGranahan N; Branca C; Kaufmann T; Dengler MA; Jost PJ
    Oncogene; 2022 Feb; 41(9):1376-1382. PubMed ID: 35091677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
    Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
    Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and VDR polymorphism.
    Maj E; Trynda J; Maj B; Gębura K; Bogunia-Kubik K; Chodyński M; Kutner A; Wietrzyk J
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105431. PubMed ID: 31326626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.
    Bigi A; Beltrami E; Trinei M; Stendardo M; Pelicci PG; Giorgio M
    Oncogene; 2016 Sep; 35(39):5132-43. PubMed ID: 26973251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
    Vaughan CA; Frum R; Pearsall I; Singh S; Windle B; Yeudall A; Deb SP; Deb S
    Biochem Biophys Res Commun; 2012 Nov; 428(1):6-10. PubMed ID: 22989750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.